Leveraging the Gut to Treat Metabolic Disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32187525.
- Also identified by DOI 10.1016/j.cmet.2020.02.014 and PMC identifier 7184629.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
25 years ago, the future of treating obesity and diabetes focused on end organs known to be involved in energy balance and glucose regulation, including the brain, muscle, adipose tissue, and pancreas. Today, the most effective therapies are focused around the gut. This includes surgical options, such as vertical sleeve gastrectomy and Roux-en-Y gastric bypass, that can produce sustained weight loss and diabetes remission but also extends to pharmacological treatments that simulate or amplify various signals that come from the gut. The purpose of this Review is to discuss the wealth of approaches currently under development that seek to further leverage the gut as a source of novel therapeutic opportunities with the hope that we can achieve the effects of surgical interventions with less invasive and more scalable solutions.
Medical subject headings
- Diabetes Mellitus, Type 2
- Gastrointestinal Tract
- Obesity